B cells in human and murine systemic lupus erythematosus

Current Opinion in Rheumatology

Volumn 16, Issue 5, 2004, Pages 505-512

  Anolik, Jennifer ^a   Sanz, Iñaki ^a  

^a Rheumatology Unit   (United States)

Author keywords

Autoreactive B cells; Human SLE; Murine SLE

Indexed keywords

AUTOIMMUNITY; B LYMPHOCYTE; CELL MATURATION; EFFECTOR CELL; HOMEOSTASIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNITY; B-LYMPHOCYTES; DISEASE MODELS, ANIMAL; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE;

EID: 4344624041     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000133660.52599.f6     Document Type: Review

References (73)

1. Chan OT, Madaio MP, Shlomchik MJ: The central and multiple roles of B cells in lupus pathogenesis. Immunol Rev 1999, 169:107-121.
2. Chan OT, Hannum LG, Haberman AM, et al.: A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 1999, 189:1639-1648.
3. Mamula MJ, Fatenejad S, Craft J: B cells process and present lupus autoantigens that initiate autoimmune T cell responses. J Immunol 1994, 152:1453-1461.
4. Chan OT, Shlomchik MJ: Cutting edge: B cells promote CD8+ T cell activation in MRL-Fas(Ipr) mice independently of MHC class I antigen presentation. J Immunol 2000, 164:1658-1662.
5. Llorente L, Richaud-Patin Y, Wijdenes J, et al.: Spontaneous production of interleukin-10 by B lymphocytes and monocytes in systemic lupus erythematosus. Eur Cytokine Netw 1993, 4:421-427.
6. Harris DP, Haynes L, Sayles PC, et al.: Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 2000, 1:475-482.
7. Moulin V, Andris F, Thielemans K, et al.: B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation. J Exp Med 2000, 192:475-482.
8. Poeck H, Wagner M, Battiany J, et al.: Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help. Blood 2004, 103:3058-3064. CpG DNA induces pDCs to stimulate naive and memory human B cells through IFN-α production.
9. Looney RJ, Anolik J, Sanz I: B lymphocytes in systemic lupus erythematosus: lessons from therapy targeting B cells. Lupus 2004, 13:1-10. This paper reviews the effects of B-cell depletion in SLE.
10. Goodnow CC, Cyster JG, Hartley SB, et al.: Self-tolerance checkpoints in B lymphocyte development. Adv Immunol 1995, 59:279-368.
11. Goodnow CC: Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires. Proc Natl Acad Sci U S A 1996, 93:2264-2271.
12. Wardemann H, Yurasov S, Schaefer A, et al.: Predominant autoantibody production by early human B cell precursors. Science 2003, 301:1374-1377. This is an elegant demonstration of the substantial autoreactive potential of mature human B cells and the need for peripheral B-cell tolerance.
13. Lieby P, Soley A, Knapp A-M, et al.: Memory B cells producing somatically mutated antiphospholipid antibodies are present in healthy individuals. Blood 2003, 102:2459-2465. This article expands the observations of Wardemann et al. [12] to human memory B cells.
14. James JA, Kaufman KM, Farris AD, et al.: An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 1997, 100:3019-3026.
15. Mockridge CI, Rahman A, Buchan S, et al.: Common patterns of B cell perturbation and expanded V4-34 immunoglobulin gene usage in autoimmunity and infection. Autoimmunity 2004, 37:9-15. Changes in global B-cell compartments and autoantibody production may be shared between patients with infectious mononucleosis (transiently) and SLE.
16. Stevenson FK, Smith GJ, North J, et al.: Identification of normal B-celi counterparts of neoplastic cells which secrete cold agglutinins of anti-I and anti-i specificity. Br J Haematol 1989, 72:9-15.
17. Bhat NM, Lee LM, Vollenhoven RV, et al.: VH4-34 Encoded antibody in systemic lupus erythematosus: effect of isotype. J Rheumatol 2002, 29:2114-2121.
18. Pugh-Bernard AE, Silverman GJ, Cappione AJ, et al.: Regulation of inherently autoreactive VH4-34 B cells in the maintenance of human B cell tolerance. J Clin Invest 2001, 108:1061-1070.
19. Cappione AJ, Pugh-Bernard AE, Anolik JH, et al.: Lupus IgG VH4.34 antibodies bind to a 220-kDa glycoform of CD45/B220 on the surface of human B lymphocytes. J Immunol 2004, 172:4298-4307. This paper demonstrates dramatic expansion of VH4.34 autoantibodies in the SLE IgG repertoire and suggests that iI-related antigens may pay a selecting role in this disease.
20. Bhat NM, Bieber MM, Spellerberg MB, et al.: Recognition of auto- and exo-antigens by V4-34 gene encoded antibodies. Scand J Immunol 2000, 51:134-140.
21. Eda S, Yamanaka M, Beppu M: Carbohydrate-mediated phagocytic recognition of early apoptotic cells undergoing transient capping of CD43 glycoprotein. J Biol Chem 2004, 279:5967-5974. N-acetyl lactosamine is aggregated in apoptotic cells and may mediate recognition of these cells by the immune system.
22. Pugh-Bernard A, Hocknell K, Cappione A, et al.: VH4-34 anti-I/i autoantibodies recognize apoptotic cells. Arthritis Rheum 2002, 46:S126.
23. Qian Y, Wang H, Clarke SH: Impaired clearance of apoptotic cells induces the activation of autoreactive anti-Sm marginal zone and B-1 B cells. J Immunol 2004, 172:625-635. Lupus-specific anti-Smith B cells are expanded and activated in the MZ and B1 compartments by antigens displayed by apoptotic cells.
24. Li Y, Li H, Ni D, et al.: Anti-DNA B Cells in MRL/Ipr mice show altered differentiation and editing pattern. J Exp Med 2002, 196:1543-1552.
25. Sekiguchi DR, Eisenberg RA, Weigert M: Secondary heavy chain rearrangement: a mechanism for generating anti-double-stranded DNA B cells. J Exp Med 2003, 197:27-39. Receptor editing by secondary heavy-chain replacement may generate autoreactivity. Together with findings by others [26,27•], the paper shows the ability of T cells to subvert B-cell tolerance.
26. Seo SJ, Fields ML, Buckler JL, et al.: The impact of T helper and T regulatory cells on the regulation of anti-double-stranded DNA B cells. Immunity 2002, 16:535-546.
27. Busser BW, Adair BS, Erikson J, et al.: Activation of diverse repertoires of autoreactive T cells enhances the loss of anti-dsDNA B cell tolerance. J Clin Invest 2003, 112:1361-1371. In a graft-versus-host model, a diverse CD4 T-cell repertoire is required for full breakdown of B-cell tolerance and expression of IgG autoantibodies.
28. Rui L, Vinuesa CG, Blasioli J, et al.: Resistance to CpG DNA-induced autoimmunity through tolerogenic B cell antigen receptor ERK signaling. Nat Immunol 2003, 4:594-600. Chronic stimulation of the BCR by self-antigen induces sustained expression of ERK (MAP) kinase and prevents nuclear factor-κB activation and plasma cell differentiation by stimulation of TLR9 (or TLR4).
29. Leadbetter EA, Rifkin IR, Hohlbaum AM, et al.: Chromatin-IgG complexes activate B cells by dual engagement of IgM and toll-like receptors. Nature 2002, 416:603-607.
30. Viglianti GA, Lau CM, Hanley TM, et al.: Activation of autoreactive B cells by CpG dsDNA. Immunity 2003, 19:837-847. This paper expands the original observation [29] that dual stimulation through the BCR and TLR9 may overcome B-cell tolerance. It also shows that mammalian DNA may stimulate tolerant anti-DNA B cells by this mechanism.
31. Bernasconi NL, Traggiai E, Lanzavecchia A: Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002, 298:2199-2202.
32. Jego G, Palucka AK, Blanck JP, et al.: Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003, 19:225-234. Important demonstration of the ability of pDCs to induce plasma cell differentiation in a T-cell-independent fashion through the sequential influence of INF-α and interleukin-6.
33. Pascual V, Banchereau J, Palucka AK: The central role of dendritic cells and interferon-alpha in SLE. Curr Opin Rheumatol 2003, 15:548-556. This paper reviews the potential roles of IFN-α in the pathogenesis of SLE.
34. Mackay F, Schneider P, Rennert P, et al.: BAFF and APRIL: a tutorial on B cell survival. Annu Rev Immunol 2002, 7:7.
35. Stohl W, Metyas S, Tan SM, et al.: B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003, 48:3475-3486. Serum levels of BLyS are increased in a subset of patients with SLE.
36. Lesley R, Xu Y, Kalled SL, et al.: Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004, 20:441-453. Increased levels of BAFF rescues autoreactive B cells from competitive elimination.
37. Rahman ZS, Rao SP, Kalled SL, et al: Normal induction but attenuated progression of germinal center responses in BAFF and BAFF-R signaling-deficient mice. J Exp Med 2003, 198:1157-1169. Together with findings by Vora et al. [38], these authors show that BAFF-mediated stimulation is required for sustained GC reactions.
38. Vora KA, Wang LC, Rao SP, et al.: Cutting edge: germinal centers formed in the absence of B cell-activating factor belonging to the TNF family exhibit impaired maturation and function. J Immunol 2003, 171:547-551.
39. Seshasayee D, Valdez P, Yan M, et al.: Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 2003, 18:279-288. This article establishes TACI as an inhibitory tumor necrosis factor receptor family with a potentially important role in the regulation of autoimmunity.
40. Avery DT, Kalled SL, Ellyard JI, et al.: BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest 2003, 112:286-297. Combined with the findings of others [41••], this paper demonstrate an important role for BCMA in the survival of long-lived plasma cells.
41. O'Connor BP, Raman VS, Erickson LD, et al.: BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004, 199:91-98.
42. Vallin H, Blomberg S, Alm GV, et al.: Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-alpha) production acting on leucocytes resembling immature dendritic cells. Clin Exp Immunol. 1999, 115:196-202.
43. Bave U, Magnusson M, Eloranta M-L, et al.: FcγRIIa is expressed on natural IFN-α-producing cells (plasmacytoid dendritic cells) and is required for the IFN-α production induced by apoptotic cells combined with lupus IgG. J Immunol 2003, 171:3296-3302. This paper extends previous observations by the same group that lupus IgG-apoptotic cell complexes are potent inducers of IFN-α production bt pDC.
44. Arbuckle MR, McClain MT, Rubertone MV, et al.: Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003, 349:1526-1533. ANA are detectable in patients with SLE years before disease onset.
45. Waters ST, McDuffie M, Bagavant H, et al.: Breaking tolerance to double stranded DNA, nucleosome, and other nuclear antigens is not required for the pathogenesis of lupus glomerulonephritis. J Exp Med 2004, jem.20031519. At least in some mouse strains, defective tolerance for nucleosomes is not required for lupus nephritis.
46. O'Keefe TL, Williams GT, Batista FD, et al.: Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J Exp Med 1999, 189:1307-1313.
47. Qian Y, Santiago C, Borrero M, et al.: Lupus-specific antiribonucleoprotein B cell tolerance in nonautoimmune mice is maintained by differentiation to B-1 and governed by B cell receptor signaling thresholds. J Immunol 2001, 166:2412-2421.
48. Khare SD, Sarosi I, Xia XZ, et al.: Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci USA 2000, 97:3370-3375.
49. Gross JA, Johnston J, Mudri S, et al.: TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000, 404:995-999.
50. Cohen PL, Caricchio R, Abraham V, et al.: Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J Exp Med 2002, 196:135-140.
51. Nishimura H, Nose M, Hiai H, et al.: Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999, 11:141-151.
52. Nishimura H, Okazaki T, Tanaka Y, et al.: Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001, 291:319-322.
53. Okazaki T, Tanaka Y, Nishio R, et al.: Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 2003,9:1477-1483. In this analysis of PD-1 knockout mice, an expanded role for this B-cell inhibitory receptor is revealed, with autoimmune cardiomyopathy as an unexpected manifestation.
54. Prokunina L, Castillejo-Lopez C, Oberg F, et al.: A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 2002, 32:666-669.
55. Prokunina L, Gunnarsson I, Sturfelt G, et al.: The systemic lupus erythematosus-associated PDCD1 polymorphism PD1.3A in lupus nephritis. Arthritis Rheum 2004, 50:327-328.
56. Li X, Wu J, Carter RH, et al.: A novel polymorphism in the Fcgamma receptor IIB (CD32B) transmembrane region alters receptor signaling. Arthritis Rheum 2003, 48:3242-3252. The discovery of a new SLE-associated polymorphism in this inhibitory FcR is particularly significant given the demonstrated alteration in B-cell signaling.
57. Kyogoku C, Kono H, Tsuchiya N, et al.: SLE-associated polymorphism of FcgammaRIIB IIe232Thr affects localization at lipid rafts and attenuation of BCR signaling. Arthritis Rheum 2003, 46:3647.
58. Enyedy EJ, Mitchell JP, Nambiar MP, et al.: Defective fcgammariib1 signaling contributes to enhanced calcium response in B cells from patients with systemic lupus erythematosus. Clin Immunol 2001, 101:130-135.
59. Yajima K, Nakamura A, Sugahara A, et al.: FcgammaRIIB deficiency with Fas mutation is sufficient for the development of systemic autoimmune disease. Eur J Immunol 2003, 33:1020-1029. Possibly depending on its epistatic interactions with other genes, FcγRIIb deficiency may produce a lupuslike phenotype.
60. Li N, Nakamura K, Jiang Y, et al.: Gain-of-function polymorphism in mouse and human Ltk: implications for the pathogenesis of systemic lupus erythematosus. Hum Mol Genet 2004, 13:171-179. Ltk gain-of-function polymorphism may impact B-cell function and may be associated with SLE.
61. Mackay F, Woodcock SA, Lawton P, et al.: Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999, 190:1697-1710.
62. Wither JE, Roy V, Brennan LA: Activated B cells express increased levels of costimulatory molecules in young autoimmune NZB and (NZB x NZW)F(1) mice. Clin Immunol 2000, 94:51-63.
63. Grimaldi CM, Michael DJ, Diamond B: Cutting edge: expansion and activation of a population of autoreactive marginal zone B-cells in a model of estrogen-induced lupus. J Immunol 2001, 167:1886-1890.
64. Amano H, Amano E, Moll T, et al.: The yaa mutation promoting murine lupus causes defective development of marginal zone B cells. J Immunol 2003, 170:2293-2301. Lupus phenotypes are observed despite abnormal development of MZ B cells.
65. Arce E, Jackson DG, Gill MA, et al.: Increased frequency of pre-germinal center B cells and plasma cell precursors in the blood of children with systemic lupus erythematosus. J Immunol 2001, 167:2361-2369.
66. Odendahl M, Jacobi A, Hansen A, et al.: Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000, 165:5970-5979.
67. Jacobi AM, Odendahl M, Reiter K, et al.: Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2003, 48:1332-1342. An extension of earlier work [66] showing a correlation between the expansion of peripheral blood plasmablasts and disease activity in SLE.
68. Huang W, Sinha J, Newman J, et al.: The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum. 2002, 46:1554-1562.
69. Grammer AC, Slota R, Fischer R, et al.: Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest 2003, 112:1506-1520. Clinical and immunologic abnormalities are improved, as detailed elsewhere [68]. IgD+ (but not IgD-) CD38+ B cells markedly decreased by treatment suggesting block in early GC reactions and/or extrafollicular reactions.
70. Kelsoe G: Therapeutic CD154 antibody for lupus: promise for the future? J Clin Invest 2003, 112:1480-1482. This paper is an insightful analysis and discussion of the article by Grammer et al. [69•].
71. Weller S, Faili A, Garcia C, et al.: CD40-CD40L independent Ig gene hypermutation suggests a second B cell diversification pathway in humans. Proc Natl Acad Sci U S A 2001, 98:1166-1170.
72. William J, Euler C, Christensen S, et al.: Evolution of autoantibody responses via somatic hypermutation outside of germinal centers. Science 2002, 297:2066-2070.
73. Looney RJ, Anolik JH, Campbell D, et al.: B cell depletion as a novel treatment for SLE. Arthritis Rheum 2004. In press.